Yuansheng Venture Capital
On July 29, AIX Insurance, a Third-party insurance technology platform, has garnered tens of millions of yuan in its Series A+ round led by Yuansheng Venture Capital, and joined by Morningside Venture Capital.
Antekang Cheng Biotechnology, a Chinese tumor EFT technology research and development company, announced the completion of its Series A financing round on July 1. The round was led by Yuansheng Venture Capital and joined by Furong Capital.
IXING Biotechnology has recently received tens of millions of yuan in Series B financing round from Yushan Capital. Earlier, the company had obtained early investment from industry funds and industrial capitals such as ZY Bio, ShiFeng Medical Instrument, and Yuansheng Venture Capital etc.